BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35857807)

  • 1. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
    Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
    Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
    Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
    J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
    Greenleaf AL
    Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.
    Zhang G; Lan B; Zhang X; Lin M; Liu Y; Chen J; Guo F
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
    Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
    Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression.
    Chen HR; Lin GT; Huang CK; Fann MJ
    Exp Neurol; 2014 Nov; 261():10-21. PubMed ID: 24999027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
    Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
    Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
    Tadesse S; Duckett DR; Monastyrskyi A
    Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
    Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
    J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
    Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
    J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
    Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
    Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
    Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
    Elife; 2018 Nov; 7():. PubMed ID: 30422115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current progress and novel strategies that target CDK12 for drug discovery.
    Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
    Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
    Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
    Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and resistance mechanism of a selective CDK12 degrader.
    Jiang B; Gao Y; Che J; Lu W; Kaltheuner IH; Dries R; Kalocsay M; Berberich MJ; Jiang J; You I; Kwiatkowski N; Riching KM; Daniels DL; Sorger PK; Geyer M; Zhang T; Gray NS
    Nat Chem Biol; 2021 Jun; 17(6):675-683. PubMed ID: 33753926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing.
    Chen HH; Wong YH; Geneviere AM; Fann MJ
    Biochem Biophys Res Commun; 2007 Mar; 354(3):735-40. PubMed ID: 17261272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation.
    Schmitz M; Kaltheuner IH; Anand K; Düster R; Moecking J; Monastyrskyi A; Duckett DR; Roush WR; Geyer M
    J Biol Chem; 2024 Jan; 300(1):105501. PubMed ID: 38016516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Mass Spectrometry Probes the Inhibitor-Induced Allosteric Activation of CDK12/CDK13-Cyclin K Dissociation.
    Bai Y; Liu Z; Li Y; Zhao H; Lai C; Zhao S; Chen K; Luo C; Yang X; Wang F
    J Am Chem Soc; 2023 May; 145(21):11477-11481. PubMed ID: 37207290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.